Marcus Schindler
Chief Tech/Sci/R&D Officer at NOVO NORDISK A/S
Profile
Marcus Schindler is Chief Scientific Officer & Executive VP-Research at Novo Nordisk A. He received a doctorate from the University of Cambridge.
Marcus Schindler active positions
| Companies | Position | Start |
|---|---|---|
| NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 2021-02-28 |
Former positions of Marcus Schindler
| Companies | Position | End |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 2021-05-27 |
| The Oxford | Chief Tech/Sci/R&D Officer | 2008-02-28 |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Chief Tech/Sci/R&D Officer | - |
AstraZeneca A/S /Denmark/
 AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Training of Marcus Schindler
| University of Cambridge | Doctorate Degree |
| University of Gottingen | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| INNATE PHARMA | Health Technology |
| Private companies | 3 |
|---|---|
| The Oxford | Consumer Services |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
AstraZeneca A/S /Denmark/
AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- Marcus Schindler
